Depression: Differential Diagnoses & Workup

References

1. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. Mar 2007;64(3):327-37. [Medline].

2. Ansorge MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol. Feb 2007;7(1):8-17. [Medline].

3. Sheikh RM, Weller EB, Weller RA. Prepubertal depression: diagnostic and therapeutic dilemmas. Curr Psychiatry Rep. Apr 2006;8(2):121-6. [Medline].

4. Spitz R. Anaclitic depression: An inquiry into the genesis of psychiatric conditions in early childhood. Psychoanalytic Study of the Child. 1946;Vol 2:313-342.

5. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother. Apr 2009;10(6):927-36. [Medline].

6. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. Jun 2009;14(6):326-33. [Medline].

7. Agency for Healthcare Research and Quality. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. AHRQ: Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=7%20&DocID=61. Accessed May 18, 2009.

8. [Best Evidence] Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. Sep 2009;166(9):980-91. [Medline].

9. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. Nov 2006;163(11):1905-17. [Medline].

10. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. Jun 2007;68(6):843-53. [Medline].

11. [Best Evidence] Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. Apr 2008;28(2):156-65. [Medline].

12. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. Apr 2009;14(4):197-206. [Medline].

13. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. Nov 2000;157(11):1873-5. [Medline].

14. Solomon DA, Leon AC, Maser JD, Truman CJ, Coryell W, Endicott J. Distinguishing bipolar major depression from unipolar major depression with the screening assessment of depression-polarity (SAD-P). J Clin Psychiatry. Mar 2006;67(3):434-42. [Medline].

15. Sachs GS. Program and abstracts of the 58th Institute on Psychiatric Services Annual Meeting. The systematic treatment enhancement program for bipolar disorder (STEP-BD): recent findings and their implications. 2006:Symposium 13.

16. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64 Suppl 13:18-25. [Medline].

17. Aronson SC, Ayres VE. Depression: A treatment algorithm for the family physician. Hospital Physician. 2000;[Full Text].

18. Brown C, Schulberg HC. Diagnosis and treatment of depression in primary medical care practice: the application of research findings to clinical practice. J Clin Psychol. Apr 1998;54(3):303-14. [Medline].

19. Charlifue S, Gerhart K. Changing psychosocial morbidity in people aging with spinal cord injury. NeuroRehabilitation. 2004;19(1):15-23. [Medline].

20. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. Jul 15 1999;46(2):212-20. [Medline].

21. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. Nov 1989;46(11):971-82; discussion 983. [Medline].

22. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. Apr 5 1995;273(13):1026-31. [Medline].

23. Leon AC, Olfson M, Broadhead WE, et al. Prevalence of mental disorders in primary care. Implications for screening. Arch Fam Med. Oct 1995;4(10):857-61. [Medline].

24. Murray ML, Wong IC, de Vries CS. Treating major depression in children and adolescents: research is needed into safer and more effective drugs. BMJ. Feb 28 2004;328(7438):524-5. [Medline].

25. Nelson JC. Augmentation strategies for treatment of unipolar major depression. Mod Probl Pharmacopsychiatry. 1997;25:34-55. [Medline].

26. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. Jul 27 1996;348(9022):233-7. [Medline].

27. Persad E. Electroconvulsive therapy in depression. Can J Psychiatry. Mar 1990;35(2):175-82. [Medline].

28. Thomas SA, Friedmann E, Wimbush F, Schron E. Psychological factors and survival in the cardiac arrhythmia suppression trial (CAST): a reexamination. Am J Crit Care. Mar 1997;6(2):116-26. [Medline].

Further Reading

Keywords

clinical depression, major depression, depression treatment, anxiety depression, major depressive disorder, MDD, unipolar depression, unipolar affective disorder, serotonin, norepinephrine, dopamine, selective serotonin reuptake inhibitors, SSRIs, tricyclic antidepressants, TCAs, norepinephrine, NE, dopamine, DA, suicide, suicidality, dysthymia, electroconvulsive therapy, ECT, electroshock therapy, shock therapy, light therapy

seasonal affective disorder, SAD, antidepressants, lithium, psychotherapy, cognitive behavioral therapy, CBT, neurasthenia, insomnia, hypersomnia, psychomotor agitation, psychomotor retardation, feelings of worthlessness, anhedonia, irritability, dementia of depression, pseudodementia, Parkinson disease, Huntington disease, multiple sclerosis, stroke, seizure disorders, systemiclupuserythematosus, SLE, autoimmune cerebritis, obstructive sleep apnea, syphilis, Lyme disease, HIV encephalopathy, Addison disease, Cushing disease, hyperthyroidism, hypothyroidism, prolactinomas

hyperparathyroidism, alcohol abuse, cocaine abuse, amphetamines abuse, marijuana abuse, narcotics abuse, inhalant abuse, bright light therapy, anxiety disorders, panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, posttraumatic stress disorder, phobia, eating disorders, bulimia, anorexia nervosa, psychosis, organic brain syndrome, hopelessness, psychosocial stress, chronic pain

Contributor Information and Disclosures

Author

Ravinder N Bhalla, MD, Assistant Clinical Professor of Child Psychiatry, University of Medicine and Dentistry of New Jersey; Medical Director, Mental Health Clinic of Passaic; Consulting Staff, Christian Health Care Center
Ravinder N Bhalla, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry
Disclosure: Bristol Meyer Squib Honoraria Speaking and teaching; Astrazeneca Honoraria Speaking and teaching

Coauthor(s)

Pascale Moraille-Bhalla, MD, Medical Director, Outpatient Clinic of Hoboken University Medical Center; Staff Psychiatrist, Mental Health Clinic of Passaic
Pascale Moraille-Bhalla, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

Medical Editor

Barry I Liskow, MD, Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Residency Program, University of Kansas School of Medicine; Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center
Barry I Liskow, MD is a member of the following medical societies: American Academy of Clinical Psychiatrists, American Academy of Psychiatrists in Alcoholism and Addictions, American Medical Association, American Psychiatric Association, and Research Society on Alcoholism
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii
Iqbal Ahmed, MBBS is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.